» Articles » PMID: 31504969

Innate Immune Cells and C-Reactive Protein in Acute First-Episode Psychosis and Schizophrenia: Relationship to Psychopathology and Treatment

Abstract

Innate immunity has been linked to initiation of Alzheimer's disease and multiple sclerosis. Moreover, risk of first-episode psychosis (FEP) and schizophrenia (Sz) is increased after various infections in predisposed individuals. Thus, we hypothesized an analogous role of innate immunity with increased C-reactive protein (CRP) in non-affective psychosis. Differential blood count, CRP, neutrophil and monocyte-macrophage activation markers, cortisol and psychotic symptoms (Positive and Negative Syndrome Scale [PANSS]) were assessed in controls (n = 294) and acutely ill unmedicated FEP (n = 129) and Sz (n = 124) patients at baseline and after 6 weeks treatment. Neutrophils, monocytes, and CRP were increased in patients vs controls at baseline (P < .001), and neutrophil and monocyte counts correlated positively with activation markers. Eosinophils were lower at baseline in FEP (P < .001) and Sz (P = .021) vs controls. Differences in neutrophils (P = .023), eosinophils (P < .001), and CRP (P < .001) were also present when controlling for smoking and cortisol, and partially remitted after antipsychotic treatment. FEP patients with high neutrophils (P = .048) or monocytes (P = .021) had higher PANSS-P scores at baseline but similar disease course. CRP correlated with PANSS-P at baseline (ρ = 0.204, P = .012). Improvement of positive symptoms after treatment correlated with declining neutrophils (ρ = 0.186, P = .015) or CRP (ρ = 0.237, P = .002) and rising eosinophils (ρ = -0.161, P = .036). In FEP, normalization of neutrophils (ρ = -0.231, P = .029) and eosinophils (ρ = 0.209, P = .048) correlated with drug dosage. In conclusion, innate immune system activation correlated with PANSS-P, supporting the immune hypothesis of psychosis. Neutrophil and monocyte counts and CRP levels may be useful markers of disease acuity, severity, and treatment response.

Citing Articles

Differences in Blood Leukocyte Subpopulations in Schizophrenia: A Systematic Review and Meta-Analysis.

Dudeck L, Nussbaumer M, Nickl-Jockschat T, Guest P, Dobrowolny H, Meyer-Lotz G JAMA Psychiatry. 2025; .

PMID: 40042836 PMC: 11883609. DOI: 10.1001/jamapsychiatry.2024.4941.


Lights and shadows of clozapine on the immune system in schizophrenia: a narrative literature review.

Liu J, Zhao W, Wang Y Metab Brain Dis. 2025; 40(2):128.

PMID: 39954151 DOI: 10.1007/s11011-025-01558-1.


Alterations in fecal bacteriome virome interplay and microbiota-derived dysfunction in patients with schizophrenia.

Tao S, Wu Y, Xiao L, Huang Y, Wang H, Tang Y Transl Psychiatry. 2025; 15(1):35.

PMID: 39880843 PMC: 11779829. DOI: 10.1038/s41398-025-03239-0.


Association between 25(OH) vitamin D and schizophrenia: shared genetic correlation, pleiotropy, and causality.

Rong G, Li X, Lu H, Su M, Jin Y Front Nutr. 2024; 11:1415132.

PMID: 39734669 PMC: 11671254. DOI: 10.3389/fnut.2024.1415132.


Schizophrenia Etiological Factors and Their Correlation with the Imbalance of the Immune System: An Update.

Lotfi N, Rezaei N, Rastgoo E, Khodadoustan Shahraki B, Zahedi G, Jafarinia M Galen Med J. 2024; 12:e3109.

PMID: 39553412 PMC: 11568428. DOI: 10.31661/gmj.v12i.3109.


References
1.
Radhakrishnan R, Kaser M, Guloksuz S . The Link Between the Immune System, Environment, and Psychosis. Schizophr Bull. 2017; 43(4):693-697. PMC: 5472105. DOI: 10.1093/schbul/sbx057. View

2.
Soehnlein O, Steffens S, Hidalgo A, Weber C . Neutrophils as protagonists and targets in chronic inflammation. Nat Rev Immunol. 2017; 17(4):248-261. DOI: 10.1038/nri.2017.10. View

3.
Schwarz E, Guest P, Rahmoune H, Harris L, Wang L, Leweke F . Identification of a biological signature for schizophrenia in serum. Mol Psychiatry. 2011; 17(5):494-502. DOI: 10.1038/mp.2011.42. View

4.
Muller N, Krause D, Dehning S, Musil R, Schennach-Wolff R, Obermeier M . Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010; 121(1-3):118-24. DOI: 10.1016/j.schres.2010.04.015. View

5.
Orlovska-Waast S, Kohler-Forsberg O, Brix S, Nordentoft M, Kondziella D, Krogh J . Cerebrospinal fluid markers of inflammation and infections in schizophrenia and affective disorders: a systematic review and meta-analysis. Mol Psychiatry. 2018; 24(6):869-887. PMC: 6756288. DOI: 10.1038/s41380-018-0220-4. View